µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y534 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â À幫±äÀ强 ¾àÁ¦ Intestinal atonia drugs causing adverse effects in therapeutic use
Y535 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼ÒÈ­Á¦ Digestants causing adverse effects in therapeutic use
Y536 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Áö»çÁ¦ Antidiarrheal drugs causing adverse effects in therapeutic use
Y537 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸ÅäÁ¦ Emetics causing adverse effects in therapeutic use
Y538 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î À§Àå°èÅë¿¡ ÀÛ¿ëÇÏ´Â ±âŸ Á¦Á¦ Other agents primarily affecting the gastrointestinal system causing adverse effects in therapeutic use
Y539 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÀÏÂ÷ÀûÀ¸·Î À§Àå°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents primarily affecting the gastrointestinal system, unspecified causing adverse effects in therapeutic use
Y54 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ¼öºÐÆòÇü°ú ¹«±â¹° ¹× ¿ä»ê ´ë»ç¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents primarily affecting water-balance and mineral and uric acid metabolism causing adverse effects in therapeutic use
Y540 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¤ÁúÄÚÆ¼ÄÚÀ̵å Mineralocorticoid causing adverse effects in therapeutic use
Y541 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¤ÁúÄÚÆ¼ÄÚÀÌµå ±æÇ×Á¦[¾Ëµµ½ºÅ׷бæÇ×Á¦] Mineralocorticoid antagonists [aldosterone antagonists] causing adverse effects in therapeutic use
Y542 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ź»ê¾ÈÈ÷µå¶ó¾ïÁ¦Á¦ Carbonic-anhydrase inhibitors causing adverse effects in therapeutic use
Y542 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Æ¼¼Å¸Á¹¾Æ¹Ìµå Acetazolamide causing adverse effects in therapeutic use
Y543 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â º¥Á¶Æ¼¾Æµð¾ÆÁø À¯µµÃ¼ Benzothiadiazine derivatives causing adverse effects in therapeutic use
Y544 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â [°í¸®]ÀÌ´¢Á¦ Loop [High-ceiling] diuretics causing adverse effects in therapeutic use
Y545 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ÀÌ´¢Á¦ Other diuretics causing adverse effects in therapeutic use
Y546 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀüÇØÁú, Ä®·Î¸® ¹× ¼öºÐÆòÇü Á¦Á¦ Electrolytic, caloric and water-balance agents causing adverse effects in therapeutic use
Y546 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸°­ Àç¼öÈ­¿°·ù Oral rehydration salts causing adverse effects in therapeutic use
Y547 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼®È¸È­¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents affecting calcification causing adverse effects in therapeutic use
Y547 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºÎ°©»ó¼± È£¸£¸ó ¹× À¯µµÃ¼ Parathyroid hormones and derivatives causing adverse effects in therapeutic use
Y547 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºñŸ¹Î D ±º Vitamin D group causing adverse effects in therapeutic use
Y548 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¿ä»ê´ë»ç¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents affecting uric acid metabolism causing adverse effects in therapeutic use
1911  1912  1913  1914  1915  [1916] 1917  1918  1919  1920